Stocks to Watch: Oracle, Acelyrin, Humacyte
12 9월 2023 - 9:03AM
Dow Jones News
By Ben Glickman
Oracle reported fiscal first-quarter growth in its cloud
business slowed sequentially and compared to the year-ago quarter.
Oracle's total revenue grew 9% to $12.45 billion, but was in line
with analysts' estimates, according to FactSet. Shares sink 9% to
$115.31 after-hours on Monday.
Acelyrin reported that one of its skin drug candidate's primary
endpoint didn't meet statistical significance by week 16 of a Phase
2b/3 trial. The company, which went public in May, said it still
had a strong financial position and expects its cash to fund
operations through important milestones for other existing drug
candidates. Shares fall 61% to $10.98 after-hours.
Humacyte said it would announce top-line data from its Phase 2/3
trial evaluating the use of implantable bioengineered human tissue
in vascular trauma repair on Tuesday morning. The biotechnology
company said Monday a separate study of its technology in the
treatment of chronic limb-threatening ischemia yielded promising
results. Shares rise 7.6% to $3.98 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 11, 2023 19:48 ET (23:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Humacyte (NASDAQ:HUMA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Humacyte (NASDAQ:HUMA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024